Test of an EGFR-targeting drug for advanced solid cancers
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have advanced cancer that can be measured on recent scans and that a doctor can biopsy (get tissue) before and after starting treatment
- Be able and willing to do a pre-treatment biopsy and an on-treatment biopsy, and share stored tumor tissue if available
- Be in good enough overall health (performance status of 1 or less)
- Have the right cancer type for the specific study “cohort” (for example, head and neck, anal canal, lung, colorectal, or skin), based on past treatments and lab results
- Be able to meet tumor testing needs, such as PD-L1 testing on real biopsy tissue (not fine-needle aspirate) and, for some cancers, HPV testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
This trial tests a new cell therapy called ACE2016 for people with advanced solid tumors that have EGFR on their surface. It may be an option if you have tried at least two other treatments (including a targeted therapy) and your cancer is still growing.
This Phase 1 study tests how safe a new drug (ABSK-021) is, what side effects it causes, and how the body processes it in people with advanced solid tumors. You may be eligible if your cancer has grown despite standard treatments or if no standard treatment exists.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.